Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts

British Journal of Cancer

Volumn 96, Issue 12, 2007, Pages 1871-1878

  Liu, J ^a   Harada, H ^a   Ogura, M ^a   Shibata, T ^a   Hiraoka, M ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Adenovirus; Gene therapy; Hypoxia inducible factor 1 (HIF 1); Hypoxia response element (HRE); Radiotherapy; Tumour hypoxia

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE; FLUCYTOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DNA RESPONSIVE ELEMENT; EMBRYO; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ADENOVIRIDAE; ANIMALS; ANOXIA; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; FEMALE; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PLASMIDS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 34250350316     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603812     Document Type: Article

References (38)

1. Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S (2003) Hypoxia-mediated tumour targeting. Gene Therapy 10: 540-549
2. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, Fang B, Roth JA (1998) Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 5: 681-688
3. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447
4. Chen CA, Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 2745-2752
5. Chen CA, Okayama H (1988) Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6: 632-638
6. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, Stratford IJ (2004) Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64: 1396-1402
7. Durand RE, Raleigh JA (1998) Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 58: 3547-3550
8. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613
9. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91
10. Greco O, Patterson AV, Dachs GU (2000) Can gene therapy overcome the problem of hypoxia in radiotherapy? J Radiat Res (Tokyo) 41: 201-212
11. Harada H, Kizaka-Kondoh S, Hiraoka M (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4: 182-193
12. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
13. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472
14. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L (1997) Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 94: 5667-5672
15. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S (2000) Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 60: 2936-2941
16. Liu J, Qu R, Ogura M, Shibata T, Harada H, Hiraoka M (2005) Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo) 46: 93-102
17. Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY (2002) Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 62: 773-780
18. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I (1996) Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 93: 1320-1324
19. Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429-441
20. Moeller BJ, Dewhirst MW (2006) HIF-1 and tumour radiosensitivity. Br J Cancer 95: 1-5
21. Mullen CA, Kilstrup M, Blaese RM (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37
22. Norris ML, Millhorn DE (1995) Hypoxia-induced protein binding to O2-responsive sequences on the tyrosine hydroxylase gene. J Biol Chem 270: 23774-23779
23. Ogura M, Shibata T, Yi J, Liu J, Qu R, Harada H, Hiraoka M (2005) A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas. Cancer Sci 96: 288-294
24. Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ (2002) Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Therapy 9: 946-954
25. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361
26. Powis G, Kirkpatrick L (2004) Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 3: 647-654
27. Rofstad EK (2000) Microenvironment-induced cancer metastasis. Int J Radiat Biol 76: 589-605
28. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107: 1-3
29. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732
30. Shibata T, Akiyama N, Noda M, Sasai K, Hiraoka M (1998) Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 42: 913-916
31. Shibata T, Giaccia AJ, Brown JM (2000) Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Therapy 7: 493-498
32. Shibata T, Giaccia AJ, Brown JM (2002) Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4: 40-48
33. Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13: 139-168
34. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549
35. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465
36. Vordermark D, Shibata T, Brown JM (2001) Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia 3: 527-534
37. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514
38. Wang GL, Semenza GL (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304-4308